Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial

AIMS: To explore details of the incidence and rates of daytime and nocturnal hypoglycaemia, levels of hypoglycaemia, and relationship to glycated haemoglobin (HbA1c), when comparing iGlarLixi versus premixed biphasic insulin aspart 30 (BIAsp 30) in the SoliMix randomized controlled trial. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrimmon, Rory J., Home, Philip, Cheng, Alice, Giorgino, Francesco, Fonseca, Vivian, Souhami, Elisabeth, Alvarez, Agustina, Picard, Pascaline, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804337/
https://www.ncbi.nlm.nih.gov/pubmed/36054624
http://dx.doi.org/10.1111/dom.14825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804337/
https://www.ncbi.nlm.nih.gov/pubmed/36054624
http://dx.doi.org/10.1111/dom.14825

Ejemplares similares